Global X Genomics & Biotechnology ETF (GNOM) Holdings $9.65 -0.55 (-5.39%) (As of 11/15/2024 ET) Add Compare Share Share Holdings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrends Top 44 GNOM HoldingsRankCompanyCurrent PriceWeightShares Held1ALNYAlnylam Pharmaceuticals$235.56-8.7%7.37%20,2512RNAAvidity Biosciences$42.18-15.6%5.74%102,6573NTRANatera$146.06-3.3%5.21%31,8264BNTXBioNTech$99.72-3.7%4.87%33,0855VCYTVeracyte$35.94-3.0%4.80%106,2046ILMNIllumina$135.05-5.1%4.53%23,723 Get the Latest News and Ratings for GNOM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. 7TECHBio-Techne$67.57-6.9%4.51%45,9128RAREUltragenyx Pharmaceutical$44.75-6.1%4.41%65,8129SRPTSarepta Therapeutics$104.54-4.2%3.87%23,45510QGENQiagen$41.27-1.9%3.83%70,18711LEGNLegend Biotech$38.19-4.3%3.69%64,51812MYGNMyriad Genetics$15.25-2.7%3.64%123,76313AAgilent Technologies$127.07-2.4%3.60%21,19514CRSPCRISPR Therapeutics$47.25+0.9%3.25%52,39515ARWRArrowhead Pharmaceuticals$18.57-13.3%3.19%125,12616Genscript Biotech CorporationN/A3.07%1,558,51817BEAMBeam Therapeutics$24.05-8.6%2.84%97,58718BMRNBioMarin Pharmaceutical$63.42-3.3%2.75%31,96019RCKTRocket Pharmaceuticals$13.98-5.7%2.65%120,90920NTLAIntellia Therapeutics$13.97-7.6%2.51%135,56721GILDGilead Sciences$88.40-4.0%2.48%21,71822TXG10x Genomics$13.34-5.5%2.26%106,05923VRTXVertex Pharmaceuticals$465.70-3.8%2.22%3,61624CDNACareDx$21.17-1.8%2.10%70,70625MRNAModerna$36.85-7.3%1.89%26,75126VIRVir Biotechnology$8.01-7.3%1.26%128,29627PACBPacific Biosciences of California$1.60-14.0%1.03%369,28028SANASana Biotechnology$2.42-6.6%0.81%172,19929FLGTFulgent Genetics$17.31-2.7%0.75%28,57830RGNXREGENXBIO$9.63-13.6%0.72%63,32731VERVVerve Therapeutics$4.79-11.0%0.58%77,79132Takara Bio Inc.N/A0.57%66,23933ALLOAllogene Therapeutics$2.27-7.7%0.51%149,99934QUREuniQure$6.21-8.0%0.50%61,22135EDITEditas Medicine$2.66-4.0%0.45%115,53736TSVT2seventy bio$3.52-10.2%0.40%67,68537PSTXPoseida Therapeutics$2.76-14.0%0.32%103,70538CRBUCaribou Biosciences$1.99-4.8%0.28%110,95339LYELLyell Immunopharma$1.100.19%167,70240BLUEbluebird bio$0.32-11.1%0.17%268,361The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here.41GRALGrail$14.80-6.4%0.07%4,03442CashN/A0.06%45,01643SCLXScilex$0.61-10.3%0.01%226,07144Japanese YenN/A0.00%1 Geographic ExposureUnited States87.3%Switzerland4.5%Cayman Islands3.2%Currency ExposureUSD77.0%HKD3.2%Sector ExposureHealth Care66.2%Energy1.3%Industry ExposureBiotechnology33.5%Health Care Equipment & Supplies23.4%Health Care Providers & Services6.1%Life Sciences Tools & Services3.2%Renewable Energy1.3%SubIndustry ExposureBiotechnology32.8%Life Sciences Tools & Services24.4%Health Care Services6.1%Health Care Equipment2.2%Renewable Energy Equipment1.3% Related Companies and Tools Related Companies HRTS Holdings BLCN Holdings TARK Holdings EMXF Holdings SPC Holdings QQMG Holdings AGNG Holdings VPN Holdings FDIF Holdings FDCF Holdings This page (NASDAQ:GNOM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
